Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMMO: Pembrolizumab + Radiation + Cocktail in Gyn Cancers
NCT03192059Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Jul 2017
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Cervical Cancer (CC), endometrial cancer (EC), uterine sarcoma, sponsored by Ghent University Hospital. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)uterine sarcoma
Beyond the preview
Go deeper on NCT03192059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192059.